Cargando…

LSD1 silencing contributes to enhanced efficacy of anti-CD47/PD-L1 immunotherapy in cervical cancer

Anti-CD47/PD-L1 immunotherapies aiming to enhance antitumor immunity are being intensively investigated and show promising results in cancer therapy; however, not all patients treated with these new drugs respond. Thus, developing new immunotherapy agents or combination treatments to enhance the eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Shengjie, Wang, Xiaoyun, Yang, Yongbing, Li, Yanli, Wu, Sufang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969769/ https://www.ncbi.nlm.nih.gov/pubmed/33731702 http://dx.doi.org/10.1038/s41419-021-03556-4

Ejemplares similares

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells
por: Lian, Shu, et al.
Publicado: (2019)

LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing
por: Le Douce, Valentin, et al.
Publicado: (2012)

LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing
por: Douce, Valentin Le, et al.
Publicado: (2014)

Targeting CD47 for cancer immunotherapy
por: Jiang, Zhongxing, et al.
Publicado: (2021)

CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy
por: Liu, Shengyang, et al.
Publicado: (2022)

LSD1 binds to HPV16 E7 and promotes the epithelial-mesenchymal transition in cervical cancer by demethylating histones at the Vimentin promoter
por: Liu, Yuan, et al.
Publicado: (2016)

Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential
por: Bao, Lei, et al.
Publicado: (2023)

Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
por: Lu, Quansheng, et al.
Publicado: (2020)

LSD1/KDM1 isoform LSD1+8a contributes to neural differentiation in small cell lung cancer
por: Jotatsu, Takanobu, et al.
Publicado: (2016)

The identification of a CD47-blocking “hotspot” and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination
por: Shi, Rui, et al.
Publicado: (2020)

ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8(+) cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy
por: Li, Chunyang, et al.
Publicado: (2015)

Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer
por: Xiong, Donghai, et al.
Publicado: (2018)

Lysine-specific histone demethylase 1A (LSD1) in cervical cancer
por: Beilner, Daniel, et al.
Publicado: (2020)

S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY
por: Zhang, Huilai, et al.
Publicado: (2023)

Inhibition of lysine-specific demethylase 1 (LSD1) prevented tumor growth and metastasis by downregulating PD-L1 expression in lung adenocarcinoma
por: He, Pengxing, et al.
Publicado: (2022)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Elevated expression of protein-L-isoaspartate O-methyltransferase-1 (PCMT1) in cervical cancer
por: Shan, Liyun, et al.
Publicado: (2022)

LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
por: Liu, Yi, et al.
Publicado: (2021)

Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model
por: Tao, Hua, et al.
Publicado: (2017)

Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
por: Liu, Hao, et al.
Publicado: (2022)

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma
por: Rigo, Valentina, et al.
Publicado: (2017)

PD‐L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell lung cancer
por: Yang, Zhenlin, et al.
Publicado: (2021)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration
por: Engstrom, Amanda K., et al.
Publicado: (2020)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

The Role of LSD1 and LSD2 in Cancers of the Gastrointestinal System: An Update
por: Malagraba, Gianluca, et al.
Publicado: (2022)

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020)

Targeting CD47 as a Novel Immunotherapy for Breast Cancer
por: Chen, Can, et al.
Publicado: (2022)

The landscape overview of CD47-based immunotherapy for hematological malignancies
por: Yang, Hua, et al.
Publicado: (2023)

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
por: Liu, Hao, et al.
Publicado: (2019)

Synergistic Re-Activation of Epigenetically Silenced Genes by Combinatorial Inhibition of DNMTs and LSD1 in Cancer Cells
por: Han, Han, et al.
Publicado: (2013)

LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer
por: Shen, Dan-Dan, et al.
Publicado: (2022)

IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy
por: Li, Song, et al.
Publicado: (2023)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene
por: Ambrosio, Susanna, et al.
Publicado: (2016)

Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8(+) T Cell Response in Hepatocellular Carcinoma
por: Peña-Asensio, Julia, et al.
Publicado: (2021)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer
por: Ding, J, et al.
Publicado: (2013)

Circulating CD137(+) T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1o58suadt0r774kiess3b95fln